John Carroll

If there’s one thing Gary Glick excels at, it’s raising money for his startups. Even in this soured financial environment.

No sooner had he closed his whopping big launch round for Odyssey Therapeutics — announcing it late last year with $218 million brimming in his coffers — than he was off and running on the Series B. And today he’s taking the wraps off of the added cash — all $168 million.

Read more

Reader Interactions

Leave A Reply